info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Paraneoplastic Syndrome Market Size

ID: MRFR//5062-HCR | 90 Pages | Author: Rahul Gotadki| June 2024

Dysregulation of the safe framework is a vital calculate the improvement of paraneoplastic syndromes. The unsusceptible reaction set off by dangerous cells can erroneously target typical tissues and organs, prompting a scope of foundational side effects. Understanding the safe framework's job in paraneoplastic syndromes is vital for restorative mediations and market contemplations.
The market is essentially formed by the neurological signs of paraneoplastic syndromes. These can incorporate problems influencing the focal sensory system, fringe nerves, and muscles. Neurological side effects add to the complexity of determination and treatment, affecting the interest for healthcare administrations and prescriptions.
The ID of cancer biomarkers and demonstrative progresses assumes an essential part in the Paraneoplastic Syndrome market. Precise and early identification of fundamental growths is fundamental for overseeing paraneoplastic syndromes. Progresses in demonstrative advances, including imaging and sub-atomic markers, influence patient results and treatment procedures.
The presence of specific autoantibodies is a trademark element of paraneoplastic syndromes. Immunological testing for these autoantibodies aids in the finding and arrangement of various syndromes. The availability of dependable and explicit immunological tests impacts market elements, working with exact analytic approaches.
Different cancer growth types are related with explicit paraneoplastic syndromes. Cellular breakdown in the lungs, ovarian disease, and bosom malignant growth, among others, may set off unmistakable syndromes. The predominance of explicit malignant growth types adds to the assortment of paraneoplastic syndromes experienced in clinical work on, forming the market scene.
The complicated idea of paraneoplastic syndromes requires multidisciplinary care including oncologists, nervous system specialists, rheumatologists, and different trained professionals. The joint effort between healthcare experts impacts the interest for administrations, affecting the market's reaction to the requirement for exhaustive patient management.
The market is affected by advancing treatment approaches for paraneoplastic syndromes. Immunomodulation, including the utilization of corticosteroids, intravenous immunoglobulin (IVIG), and immunosuppressive specialists, is a typical helpful technique. Progresses in treatment choices and the presentation of novel immunomodulatory drugs influence patient results and market patterns.

Paraneoplastic Syndrome Market Scenario


The paraneoplastic syndrome market is expected to grow USD 460 Million at a CAGR 5.80 % during the forecast period 2023 to 2030.

A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically seen in the middle-aged population to older population. This syndrome mostly occurs with patients suffering from lung, ovarian, or breast cancers.  

Numerous factors are anticipated to drive the growth of this market such as the increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle, increasing geriatric population, and increasing occurrence of breast cancer, among women. According to the American Autoimmune Association, 50 million people suffered from autoimmune disorders in the US in 2017.  

Increasing collaborations among various research institutes for the development of novel diagnostic techniques for the diagnosis of the paraneoplastic syndrome are expected to drive the growth of this market.

Despite the drivers, factors such as unfavorable reimbursement scenario and stringent regulatory policies may hamper the growth of the market during the assessment period.

Segmentation

The paraneoplastic syndrome market has been segmented into types, diagnosis, treatment, and end users. Based on types, the market is segmented into cutaneous paraneoplastic syndrome, gastro-intestinal paraneoplastic syndrome, endocrine paraneoplastic syndrome, hematologic paraneoplastic syndrome, renal paraneoplastic syndrome, rheumatologic paraneoplastic syndromes, and neurologic paraneoplastic syndrome.

The market on the basis of diagnosis has been segmented into blood test, spinal tap (lumbar puncture), and

imaging tests. Imaging tests are further sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and PET plus CT.

The market, by treatment, has been segmented into medication and therapies. Medication is further sub-segmented into corticosteroids, immunosuppressants, anti-seizure medications, plasmapheresis, and intravenous immunoglobulin (IVIg). On the basis of therapy, the market is further sub-segmented into physical therapy and speech therapy.

Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers, and ambulatory care centers.

Key players

Some of the key players in the global paraneoplastic syndrome market are Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation,

York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.

Regional Market Summary

Global Paraneoplastic Syndromes Market Share (%), by Region, 2018


Paraneoplastic Syndromes Market


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC)


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The paraneoplastic syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European paraneoplastic syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The paraneoplastic syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The paraneoplastic syndrome market in the Middle East and Africa has been segmented into the Middle East and Africa.


Geographically, the Americas is anticipated to dominate the global paraneoplastic syndrome market. The market growth in this region is attributed to the increasing geriatric population with the paraneoplastic disorder, investment in research and development, and technological advancements. However, increasing approval of novel neurological diagnosis tools in this region is boosting the market in this region.


Europe is expected to be the second largest market in the globe owing to the increasing number of geriatric populations, increasing government expenditure for autoimmune disorders, the presence of disposable income, and increasing consumption of tobacco in this region.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of paraneoplastic disorder and cancer-related problems in developing countries, increasing disposable income, and growing healthcare expenditure.


The Middle East and Africa is expected to account for the lowest market share in the global paraneoplastic syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.


Global Paraneoplastic Syndrome Market, by Types



  • Cutaneous Paraneoplastic Syndrome

  • Gastro-Intestinal Paraneoplastic Syndrome

  • Endocrine Paraneoplastic Syndrome

  • Hematologic Paraneoplastic Syndromes

  • Renal Paraneoplastic Syndrome

  • Rheumatologic Paraneoplastic Syndromes

  • Neurologic Paraneoplastic Syndrome


Global Paraneoplastic Syndrome Market, by Diagnosis



  • Blood test

  • Spinal tap (lumbar puncture)

  • Imaging tests

  • Computerized tomography (CT)

  • Magnetic resonance imaging (MRI)

  • Positron emission tomography (PET)

  • PET plus CT


Global Paraneoplastic Syndrome Market, by Treatment



  • Medication

  • Corticosteroids

  • Immunosuppressants

  • Anti-seizure medications

  • Medications to enhance nerve to muscle transmission

  • Plasmapheresis

  • Intravenous immunoglobulin (IVIg)

  • Therapies

  • Physical therapy

  • Speech therapy


Global Paraneoplastic Syndrome Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Ambulatory Care Centers


Global Paraneoplastic Syndrome Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific



  • Middle East & Africa



  • Middle East

  • Africa


Global Paraneoplastic Syndrome Market, by Key Players



  • Healthineers

  • Koninklijke Philips N.V.

  • General Electric Company

  • Esaote SpA

  • NeuroLogica Corporation

  • Masimo Corporation

  • York Instruments Ltd

  • Neusoft Medical Systems

  • Canon Medical Systems Corporation


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations

  • Healthcare providers

  • Research institutes and academic centers

  • Government associations

  • Market research and consulting

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.